Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
| Status: | Completed |
|---|---|
| Conditions: | High Cholesterol |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 1/23/2019 |
| Start Date: | February 2011 |
| End Date: | October 2011 |
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
The primary objective of this study is to evaluate the safety and tolerability of repeated
doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an
investigational drug that is currently being studied as a lipid lowering agent.
doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an
investigational drug that is currently being studied as a lipid lowering agent.
Inclusion Criteria:
- LDL-C must be greater or equal to 130 mg/dl
- BMI must be between 18.5 and 40 kg/m2
- Japanese volunteers must have 4 Japanese grand parents born in Japan
Exclusion Criteria:
- History of cardiovascular or cerebrovascular event during the past year.
- Poorly controlled type 1 or type 2 diabetes mellitus
- Subjects who have taken lipid lowering therapies within the last 3 months of
screening.
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials